吡格列酮治疗2型糖尿病轻度认知功能障碍患者的临床疗效

发布时间：2018-05-27 21:31

本文选题：吡格列酮 + 型糖尿病　；参考：《中国老年学杂志》2017年17期

【摘要】：目的探讨吡格列酮对2型糖尿病(T2DM)患者轻度认知功能障碍(MCI)的临床疗效。方法采用自身对照的方法,选取T2DM合并MCI患者56例,在常规降糖治疗的基础上给予盐酸吡格列酮15 mg/d口服治疗,疗程2年。于治疗前检测空腹胰岛素(FINs),C肽(FCP),空腹血糖(FPG),血压,血脂,血尿酸(UA),胰岛素样生长因子(IGF)-I,转化生长因子(TGF)-β1,以及动态血糖监测;同时给予蒙特利尔认知评价量表(MoCA)、MMSE以及P300评定;治疗1年和2年后再次抽血化验上述指标和心理评定。结果与治疗前比较,在吡格列酮治疗2年后糖化血红蛋白(Hb A1c)、FINs水平、HOMA-IR、P300潜伏期缩短,TGF-β1水平下降,IGF-I水平显著增加(P0.05);Mo CA评分显著增加、MMSE评分显著增加、P300潜伏期和波幅显著降低(P0.01)。结论吡格列酮治疗能够改善和延缓T2DM患者的认知功能减退,治疗需要时间长,可能与改善胰岛素抵抗有关。
[Abstract]:Objective to investigate the clinical effect of pioglitazone on mild cognitive impairment (MCI) in patients with type 2 diabetes mellitus (T2DM). Methods 56 patients with T2DM combined with MCI were treated with pioglitazone hydrochloride for 15 mg/d for 2 years on the basis of conventional hypoglycemic therapy. Before treatment, fasting insulin FINS C peptide (FCPG), fasting blood glucose (FPG), blood pressure (BP), blood lipid (BP), serum uric acid (UAA), insulin-like growth factor (IGF) -I, transforming growth factor TGF- 尾 _ 1 (TGF- 尾 _ 1), and dynamic blood glucose monitoring were detected, and the Montreal Cognitive Assessment scale (MoCAMMSE) and P300 were used to assess. After 1 and 2 years of treatment, the above indexes and psychological evaluation were tested again. Results after 2 years of pioglitazone treatment, the levels of HbA1cFINs and HOMA-IRP300 decreased. IGF-I increased significantly. Conclusion pioglitazone treatment can improve and delay cognitive impairment in T2DM patients, which may be related to the improvement of insulin resistance.
【作者单位】：南京医科大学附属无锡市精神卫生中心同仁康复医院老年科;南京医科大学附属无锡市精神卫生中心中西医结合精神科;南京医科大学附属无锡市同仁康复医院神经康复科;南京医科大学附属无锡市精神卫生中心实验室;南京医科大学附属无锡市人民医院内分泌科;
【基金】：江苏省卫生厅预防医学项目(No.Y2012032) 无锡市科技局计划指导项目(No.CSZ00N1236)
【分类号】：R587.2

【相似文献】